African American (AA) patients with systemic sclerosis (SSc; scleroderma) are reported to have a worse overall prognosis than Caucasians, which might be explained by a younger age of disease onset, higher frequency of diffuse cutaneous involvement, more severe lung involvement, and younger age at onset of pulmonary artery hypertension (PAH) 1, 2, 3, 4, 5 .
Anti-U3-RNP, or anti-fibrillarin antibody (AFA), is directed against a 35-kDa protein component of a nucleolar ribonucleoprotein called fibrillarin, which is an early marker for the formation site of nucleolus in dividing cells 6 . The frequency of AFA differs across ethnic groups, ranging from zero in a large cohort of Italian patients with SSc 7 to 50% in an African American SSc population 8 . The higher prevalence of AFA in the sera of AA patients with SSc has been noted in several studies 9, 10, 11, 12, 13 .
Studies have shown that HLA-DRB1*08 and DQB1*03:01 are associated with AFA in African Americans 10, 14 . Clinically, SSc patients with AFA have been reported to have younger ages of disease onset, higher frequency of diffuse cutaneous involvement, PAH, SSc-associated musculoskeletal and cardiac involvement, and lower frequency of arthritis 9, 10, 11, 15, 16, 17 . However, there is a lack of large robust studies on the immunogenetic associations, clinical manifestations, and survival effect of AFA in AA patients with SSc.
We compared the HLA class II alleles in AA SSc patients with AFA with unaffected controls matched for ethnicity and sex and with SSc patients without AFA. We investigated the clinical features and survival effect of AFA in AA patients with SSc.
MATERIALS AND METHODS
Study population. Between 1985 and 2010, 3033 patients with SSc were enrolled in the following cohorts: (1) the Genetics versus ENvironment In Scleroderma Outcomes Study (GENISOS) 3, 5, 18 ; (2) the NIH/NIAMS Scleroderma Family Registry and DNA Repository 19 ; and (3) the Division of Rheumatology, University of Texas Health Science Center at Houston (UTHSC-H) 10 . Patients were included if they met the American College of Rheumatology (formerly American Rheumatism Association) classification criteria for SSc 20 or had at least 3 of the 5 CREST features (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) 21 . We included all AA patients from these cohorts (n = 278). Patients enrolled in more than one of the cohorts were identified and duplicate entries were omitted. We enrolled 328 unaffected AA controls to determine any HLA class II allele associations with AFA. The unaffected AA individuals were volunteers with no personal or family history of SSc or other autoimmune disease by screening questionnaire. All study subjects enrolled (SSc patients and unaffected controls) provided written informed consent, and the institutional review board of all participating institutions approved the study.
Autoantibody profile and HLA class II allele genotyping. All autoantibody determinations and HLA class II allele typing were conducted in the Division of Rheumatology at UTHSC-H and the Mitogen Advanced Diagnostics Laboratory, University of Calgary, Calgary, Canada. Antinuclear antibodies (ANA) and anticentromere antibodies were determined using indirect immunofluorescence with HEp-2 cells as substrate (Antibodies Inc., Davis, CA, USA). Passive immunodiffusion gels against calf thymus extract were used to examine sera for antitopoisomerase-I (ATA; Scl-70), anti-Ro/SSA, anti-La/SSB, and anti-U1-RNP autoantibodies (Inova Diagnostics, San Diego, CA, USA). Anti-RNA polymerase III (RNAP III) was detected by ELISA kits (MBL Co. Ltd., Nagoya, Japan) and AFA were determined by a line immunoassay at a serum dilution of 1:1000 using purified recombinant fibrillarin protein (Euroline-WB; Euroimmun, Lubeck, Germany) in patients who had a positive ANA in antinucleolar pattern on the indirect immunofluorescence.
As described 5, 22 , we genotyped HLA class II alleles (DRB1, DQA1, DQB1, and DPB1) on extracted and purified genomic DNA. Further, we examined the HLA class II allele-binding peptide using the ProPred MHC Class II Binding Peptide Prediction Server 23 in order to predict binding peptides of human fibrillarin protein. This prediction is based on quantitative matrices derived from the literature 23, 24 .
Clinical manifestation. Age, sex, disease type (categorized as limited or diffuse cutaneous involvement at time of enrollment 21 ), disease duration (calculated from the onset of the first non-Raynaud's phenomenon symptom attributable to SSc), and modified Rodnan skin score (MRSS) 25 were recorded.
To assess the severity of individual organ system involvement, the Medsger severity indices 13,26 of 8 organ systems were measured: peripheral vessels, skin, joints/tendons, skeletal muscle, gastrointestinal (GI) tract, lung, heart, and kidney. However, these data were available only for the patients enrolled in the GENISOS cohort (n = 78). The presence of digital ulcers was determined based on the participating rheumatologist's clinical assessment. Arthritis was defined as presence of joint swelling and tenderness on examination not attributable to osteoarthritis, crystalline arthropathy, or trauma. A decrease in range of motion > 25% in at least one joint axis was defined as joint contracture. Dysphagia, diarrhea attributable to SSc, and history of SSc renal crisis were recorded. Electrocardiography and 2-dimensional echocardiography findings and/or presence of an auscultatory friction rub determined the presence of pericarditis or clinically significant pericardial effusion.
As described 18 , pulmonary function tests were obtained at enrollment. Interstitial lung fibrosis, defined as chest radiograph showing fibrosis and/or forced vital capacity (FVC) < 75% of predicted value, was recorded.
For the purpose of our review, PAH was defined if the patient had (1) mean pulmonary artery pressure ≥ 25 mm Hg on right heart catheterization; (2) right ventricular systolic pressure ≥ 40 mm Hg on 2-dimensional echocardiography; or (3) if the ratio of FVC% predicted to diffusion capacity of carbon monoxide (DLCO)% predicted was ≥ 1.6. Serum creatine kinase (CK) levels were recorded and myositis was diagnosed if the patient had proximal muscle weakness with at least one of the following: elevated levels of CK, features of myositis on electromyography, and/or a characteristic muscle biopsy.
Death search. The vital status of patients was determined through the National Death Index (NDI) at the US Centers for Disease Control and Prevention, which provided data up until 2007. We then reviewed the US Social Security Death Index (SSDI) to update our results as of August 2010. SSDI is an online death search tool that provides fatality reports based on death certificates and family confirmation. Patients not found on NDI or SSDI were assumed to be alive.
Statistical analysis.
Homozygosity for alleles at each of the tested HLA loci was not suggestive of recessive inheritance, regardless of whether the referent comparison group comprised disease-free controls or AFA-negative cases. There were too few homozygous subjects to distinguish additive from dominant modes of inheritance, regardless of the referent. Therefore, a dominant mode of inheritance approach was used to compare the HLA association with AFA. Heterozygosity and homozygosity for a particular allele were both recoded as "1" in a binary (zero or 1) variable created for each specific HLA gene of interest. In other words, subjects negative for the gene on both their alleles for the particular HLA locus were coded "0" for the gene on the new binary variable. Bonferroni correction for multiple comparisons was performed for HLA allelic analyses.
Age, sex, disease type, and disease duration of AFA-positive and AFAnegative patients were evaluated utilizing chi-square and Student t test accordingly. SSc clinical manifestations might have changed over the disease course; therefore logistic regression was used to adjust for disease duration as a possible confounding factor in clinical features and to examine the independent effect of AFA.
We utilized Cox proportional hazards regression analysis to examine the association of AFA with survival. We investigated the potential association of relevant HLA class II with survival of the AA patients with SSc. Survival analysis was corrected for age at enrollment. Survival was calculated from the date of enrollment.
ATA and AFA are the 2 most common antinuclear antibodies among AA patients with SSc. We also compared the clinical features and survival of AA scleroderma patients with AFA (n = 50) to those with ATA (n = 61) for comparative analysis between more homogeneous groups.
All the statistical analyses were performed with SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata 11 (StataCorp., College Station, TX, USA). Hypothesis testing was 2-sided with a p ≤ 0.05 significance level.
RESULTS

Study population, disease, and autoantibody characteristics.
All 278 AA scleroderma patients from the 3 cohorts were included in the study. The mean age (± SD) of patients at enrollment was 46.9 (13.9) years, and 237 (85.3%) were female. At enrollment, 171 (61.5%) AA patients with SSc were diagnosed with diffuse cutaneous involvement. Average disease duration (± SD) was 6.0 (6.5) years.
ANA on HEp-2 substrate were detected in 93.1% of AA SSc patients. ATA, RNAP-III, and AFA were present in 21.8%, 15.4%, and 18.5% of patients, respectively (Table 1) . HLA class II allelic frequencies. As illustrated in Table 2 , comparison of HLA class II allelic frequencies of AFA-positive patients with 329 ethnically matched unaffected controls revealed the HLA-DRB1*08:04 allele more frequently in AFA-positive patients (47.6% vs 6.4%, respectively; OR 11.52, 95% CI 5.43, 24.40; corrected p < 0.0001). Two other alleles located on the same haplotype, DQA1*04:01 and DQB1*03:01, had similar patterns. However, the increased frequency of DQA1*04:01 was not statistically significant.
The frequency of HLA-DRB1*08:04 in AFA-positive patients also was higher in comparison to AA patients without AFA, even after correction for multiple comparisons (47.6% vs 14.9%; OR 5.21, 95% CI 2.44, 11.09; corrected p = 0.0002). Both HLA-DQA1*04:01 and DQB1*03:01 showed similar trends. However, neither of them remained significant after correction for multiple comparisons.
HLA-DPB1*01:01 was also seen more frequently among AFA-positive AA patients compared to unaffected controls and SSc patients without AFA, whereas HLA-DRB1*11:01 seemed to be protective. HLA-DPB1*01:01 and HLA-DRB1*11:01 are not in linkage disequilibrium with HLA-DRB1*08:04. However, the association of these 2 alleles with AFA did not withstand correction for multiple comparisons. The frequencies of all relevant HLA class II alleles in AA SSc patients and unaffected individuals are illustrated in Table 3 . HLA-DRB1*08:04 binding peptides. Using virtual matrix for HLA-DRB1*08:04, at a threshold of 1% (the percentage best scoring natural peptides), we identified 4 binding peptides (FRSKLAAAI, FRGRGRGGG, IHIKPGAKV, and FVISIKANC) from the human fibrillarin protein that could serve as potential binding sites within the antigen-binding groove. Clinical features. AA SSc patients with AFA were younger at disease onset (p = 0.004) but sex, disease type, and duration were not significantly different compared to AA SSc patients with AFA. Table 4 illustrates the comparison of clinical manifestations between AFA-positive and AFA-negative AA patients with SSc.
After adjustment for disease duration, AA SSc patients with AFA were 3.31-times more likely to have digital ulcers (p = 0.014). Diarrhea and pericarditis occurred more frequently in AFA-positive AA SSc patients (OR 4.84, p = 0.019; OR 2.45, p = 0.092, respectively) than AA patients without AFA. However, there were no differences between AFA-positive and AFA-negative AA SSc patients in MRSS, dysphagia, PAH, SSc-associated interstitial lung fibrosis, FVC and DLCO predicted values, SSc renal crisis, myositis (Table 4) . Survival analysis. At the time of analysis, 30% of AFA-positive AA SSc patients and 29.5% of AFA-negative patients were deceased (Table 4) . After correction for age at enrollment, AFA-positive patients did not have different survival compared to AFA-negative patients (hazard ratio = 0.79, p = 0.493). In addition, none of the relevant HLA class II was a predictor of mortality in AA patients with SSc (Table 5) . AFA and ATA among AA patients with SSc. Although age at onset of the first non-Raynaud's symptom was not statistically different between these 2 groups, the AA scleroderma patients with AFA had higher frequency of digital ulcers, and lower GI tract involvement, pericarditis, and Medsger peripheral vascular severity index scores (Table 6) . AFA-positive patients had lower Medsger lung severity index, higher FVC and DLCO predicted values, and fewer cases of PAH. Despite less severe lung disease, after adjusting for age of disease onset, AFA-positive patients did not have better or worse survival compared to ATA-positive (Table 5) .
DISCUSSION
At a frequency of 18.5%, AFA is the second most common antinuclear antibody among AA patients with SSc (second to ATA). Our report represents the first study of the genetic associations, clinical manifestations, and infuence of AFA on survival in a large population of AA patients with SSc.
Distinct HLA class II allelic associations of SSc-specific autoantibodies in different ethnic groups have been described in several studies 5, 10, 14, 27, 28 . In a large sample of Caucasian patients, we previously reported that HLA-DRB1 30 reported no difference in frequency of HLA-DRB1*08:04 between 321 AA patients with RA and 564 unaffected individuals. Previously, we showed that HLA-DRB1*08:04 might be a susceptibility gene for SSc among AA 14 ; whereas the results of the current study demonstrated that the higher frequency of HLA-DRB1*08:04 with SSc in AA patients is mainly driven by its strong association with AFA in this ethnic group. Through the Binding Peptide Prediction Server 23 for HLA-DRB1*0804, we identified 4 potential binding peptides from the human fibrillarin protein that could serve as potential binding sites within the antigenbinding groove. The large effect sizes (Table 2 ) and predicted binding peptides should prompt more studies to investigate potential causal and/or environmental relationships of these autoantibodies.
An animal model for induction of AFA has been studied extensively and may provide clues to an environmental trigger in humans with AFA-positive SSc. Certain mouse strains possessing specific H2 (the murine counterpart for HLA) haplotypes develop a non-SSc autoimmune disease and high-titer AFA following administration of mercuric chloride or silver nitrate 31, 32, 33, 34 . Of note, one study of urinary 4 The mercury levels in SSc patients noted higher levels in those with AFA. However, this observation did not maintain statistical significance following corrections 35 . Interestingly, heavy metals have been noted to be highly concentrated in the nucleolus 36 . It was reported by Pollard, et al 37 that most if not all of the SSc-specific autoantigens were at some time during their life cycle localized to the nucleolus. Clearly, larger and more targeted studies of heavy metal and other environmental exposures are warranted in AFA-positive SSc patients, perhaps selected for the associated HLA class II alleles (DRB1*13:02 in Caucasians and DRB1*08:04 in AA) and AFA-negative SSc patients, as well as well matched healthy controls. Confirming our previous findings 10 , we showed that HLA-DQB1*03:01 had a higher frequency among AFA-positive AA patients compared to unaffected AA individuals. However, there was no difference between AFA-positive and negative AA patients with SSc.
AA patients with SSc are younger at SSc onset compared to other ethnic groups 1, 2, 5, 28 . Moreover, other studies show that SSc patients with AFA have younger age of disease onset 2, 12, 13, 16, 17 . In support of these findings, we demonstrated that AA SSc patients with AFA had younger age of onset in comparison to AA patients without AFA.
The higher Medsger peripheral vascular severity index and prevalence of digital ulcers in AA patients with AFA compared to those without AFA are novel findings. These findings were also present when we compared AFA-positive and ATA-positive AA patients with SSc. Previous studies have shown higher rates of digital ulcers among AA patients with SSc compared to Caucasians 2,4 . Higher frequencies of AFA in AA might contribute to this finding. Steen 12 reported higher frequency of digital ulcers in AFA-positive patients; however, these findings were not stratified for ethnic background.
In agreement with studies reporting more severe GI involvement in AFA-positive patients (regardless of ethnicity) 10,12 , we observed a higher frequency of SSc-associated diarrhea in AFA-positive AA patients. The higher frequency of lower GI tract involvement was more significant when AFA-positive AA patients were compared to ATA-positive patients. It is possible that AFA-positive patients have more severe lower GI tract hypomotility and bacterial overgrowth that contribute to diarrhea. Our results imply a less severe lung involvement among AFA-positive AA patients with SSc, as assessed by lower scores of the Medsger lung severity index. The comparison of AFA-positive and ATA-positive AA scleroderma patients further demonstrated less severe lung involvement (higher FVC and DLCO predicted values and lower Medsger lung severity index). In agreement with our findings, in an ethnically homogenous cohort of Japanese patients with SSc, AFA-positive patients had less severe lung involvement 17 . While data from several multiethnic cohorts suggested a higher frequency of isolated PAH and/or pulmonary fibrosis in the SSc patients with AFA 9,10,12,13,38 , these comparisons were not adjusted for ethnicity or for other antibodies, i.e., ATA, as potential confounders. Therefore, the higher frequency of lung fibrosis and PAH might be due to a sizeable AA population in the AFA-positive group and a large number of Caucasian SSc patients in the AFA-negative group. More severe SSc-associated lung involvement in AA patients with SSc compared to other ethnic groups has been reported in several studies 2, 18, 28, 39, 40 . Based on our findings, AFA-positive AA patients with SSc have a higher prevalence of pericarditis, compared to AFA-negative as well as and ATA-positive patients. This is in agreement with studies indicating higher frequency of cardiac involvement in AFA-positive 10, 12 and AA patients with SSc 39 .
Our study did not confirm reports of worse 13 or better 11 survival in AFA-positive patients with SSc. The poorer survival of AFA-positive patients in one report 13 might be attributable to the confounding or modifying effects of ethnicity in studies that are not stratified by ethnicity, as AA ethnicity is associated with AFA positivity as well as poorer survival 1, 10, 12, 13 .
This study has limitations. Although potentially important, data on heavy metal exposure were not collected. Medsger severity indices were available only for patients from the longitudinal GENISOS cohort. High-resolution computed tomography scans and echocardiography were not performed on all patients, which might have led to underreporting of pulmonary involvement; and despite being the largest genetic study reported to date in AA patients with SSc, the findings might be underpowered to detect more subtle HLA associations with AFA in the AA population.
Anti-fibrillarin antibody was the second most common antinuclear antibody in African Americans with SSc. Presence of AFA was strongly associated with the HLA-DRB1*08:04 in the AA patients with SSc. In addition, AA SSc patients with AFA had a younger age of disease onset, higher frequency of digital ulcers and pericarditis, more severe lower GI involvement, and less severe pulmonary involvement. Future studies should focus on environmental factors, such as heavy metal exposure, that may influence the B cell response and the immunopathology of the disease.
